Virax Biolabs Group Limited to Present at H.C. Wainwright’s 24th Annual Global Investment Conference in New York, NY

Virax Biolabs Announces NASDAQ Closing Bell Ringing to Celebrate Initial Public Offering

Benzinga Interview: 4th of August 2022, with Chief Executive, James Foster

Virax Biolabs Introduces Monkeypox and Varicella-Zoster Viruses Real-Time PCR Detection Kit

Virax Biolabs Group Limited Completes Initial Public Offering; Shares Begin Trading Today on NASDAQ Capital Market as VRAX

Virax Biolabs Group Limited Announces Pricing of $6.75 Million Initial Public Offering

Virax Biolabs Announces the Formation of Advisory Board of Industry Leaders

Virax Biolabs Introduces New Board of Directors, Announces Members

Virax Biolabs Receives Ethical Approval for its Virax Immune COVID-19 Analytical Performance Study from the SBEBO Foundation for the Assessment of Ethics of Biomedical Research

Virax Biolabs Announces the Appointment of Jason D. Davis as Chief Financial Officer